SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| McEvoy Ashley | President and CEO, Director | 2026-08-21 | Open-market buy | 1100 | $162K |
| Davis Lisa Blair | SVP, Chief HR Officer | 2026-08-01 | Tax withholding | 244 | $40K |
| MAZELSKY JONATHAN JAY | Director | 2026-07-01 | Grant/award | 1355 | $0 |
| Huffines Robert Luther | Director | 2026-06-30 | Grant/award | 144 | $23K |
| BORIO LUCIANA | Director | 2026-06-03 | Open-market sell | 418 | $60K |
| STONESIFER TIMOTHY C. | Director | 2026-06-03 | Open-market buy | 2790 | $400K |
| WEATHERMAN ELIZABETH H | Director | 2026-06-03 | Open-market buy | 3450 | $497K |
| BORIO LUCIANA | Director | 2026-05-20 | Grant/award | 1660 | $0 |
| Frederick Wayne A.I. | Director | 2026-05-20 | Grant/award | 1660 | $0 |
| Hopfield Jessica | Director | 2026-05-20 | Grant/award | 1660 | $0 |
| Huffines Robert Luther | Director | 2026-05-20 | Grant/award | 1660 | $0 |
| MINOGUE MICHAEL R | Director | 2026-05-20 | Grant/award | 1660 | $0 |
| STONESIFER TIMOTHY C. | Director | 2026-05-20 | Grant/award | 1660 | $0 |
| Scannell Timothy J | Director | 2026-05-20 | Grant/award | 1660 | $0 |
| WEATHERMAN ELIZABETH H | Director | 2026-05-20 | Grant/award | 1660 | $0 |
| McEvoy Ashley | President and CEO, Director | 2026-05-13 | Tax withholding | 1411 | $210K |
| Panos Michael | EVP and CCO | 2026-04-01 | Grant/award | 2777 | $0 |
| Huffines Robert Luther | Director | 2026-03-31 | Grant/award | 111 | $23K |
| Benjamin Eric | EVP and COO | 2026-02-27 | Tax withholding | 644 | $159K |
| Benjamin Eric | EVP and COO | 2026-02-27 | Tax withholding | 268 | $66K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
GLP-1 drug adoption and a new Section 232 tariff investigation represent the sharpest new threats to Insulet's demand and margin outlook, compounding broad operational and supply chain escalations across Malaysia manufacturing, international expansion, and pandemic disruption scenarios. Governance risk is elevated by concurrent CEO and CFO transitions, though partially offset by remediation of the IT material weakness and retirement of convertible notes. The net picture is meaningfully worse across macro, competitive, operational, and technology themes, with only limited structural relief on the capital side.
11 company-specific · 2 eased/removed · 4 common-mode
New disclosure of specific Section 232 investigation into medical device tariffs with potential to override current exemptions, directly threatening supply chain costs and margins.
Expansion of U.S. tariffs could have a material adverse effect on our financial results. Tariffs, sanctions or other trade barriers imposed by the U.S. (and countermeasures by non-U.S. governments)…
New disclosure of GLP-1 drug adoption risk materially reducing type 2 diabetes progression and market demand for Omnipod products.
Technological breakthroughs in diabetes monitoring, treatment, or prevention could render our Omnipod products obsolete or less desirable. The diabetes treatment market is subject to rapid…
New disclosure of 2025 CEO and CFO changes with integration and continuity risks. Escalates governance risk from general talent retention to specific leadership transition concerns.
General Risks Our success depends on our ability to attract, motivate, and retain key personnel. As Insulet continues to quickly grow, our success is highly dependent on attracting the right talent…
Risk escalated: added new growth drivers (international expansion, type 2 diabetes market entry), expanded operational strain scope, and added cost-effectiveness manufacturing risk.
If we do not effectively manage our rapid growth, our business resources may become strained and we may not be able to deliver our products in a timely manner, which could adversely affect our…
Added emerging competitor Beta Bionics, new risk of losing technology leader position, and new risk from authoritative endorsements of competing products.
Risks Related to Competition and Product Development Our failure to compete effectively would negatively impact our revenue and results of operations. The competitive landscape in our industry…
Added reimbursement risk from third-party payors as new consequence of failed clinical trials. Removed diabetes association endorsement risk. Net effect escalates clinical trial failure impact.
Future market or clinical studies may be unfavorable to our Omnipod products and their efficacy, which could hinder our sales efforts and have a material adverse effect on our business, results of…
Added explicit language that IP failure could limit ability to sell products "profitably, or at all" and impair competitive position, escalating severity.
Risks Related to our Intellectual Property We may be unable to adequately protect our intellectual property rights, which could limit our ability to sell our products profitably, or at all, and cause…
Added specific pandemic supply-chain disruption risk with detailed operational impact scenarios (manufacturing, distribution, sterilization, worker shortages), escalating from generic pandemic reference to material operational vulnerability.
Risks Related to Economic Conditions and Operating Internationally The continuing worldwide macroeconomic and geopolitical uncertainty as well as the impact of another global pandemic may adversely…
New disclosure of reimbursement risk from foreign healthcare systems; international sales grew from 25% to 28% of revenues, escalating exposure to geopolitical and trade risks.
The international nature of our business subjects us to additional business risks that may have an adverse effect on our financial condition or results of operations. International expansion is a key…
Malaysia manufacturing facility now explicitly included in supply chain disruption risk. New opening sentence emphasizes material adverse effect on manufacturing ability. Risk scope expanded.
Our inventory is produced and maintained in a limited number of locations, including one operated by a third party in China, and any loss could have a material adverse effect on our ability to…
Risk escalated with new specific failure modes: compromised quality, reduced productivity, higher defect rates, increased waste, and supplier strain. Language shifted from conditional to more definitive adverse effects.
Our manufacturing process is highly complex and subject to regulation; as demand for our products increase, we may experience manufacturing difficulties, including not effectively managing the…
Removal of convertible notes dilution risk indicates notes were retired, redeemed, or converted. Material reduction in capital structure risk and shareholder dilution exposure.
Conversion of any of our Convertible Senior Notes may dilute the ownership interest of existing stockholders or depress our stock price. The conversion of some or all our Convertible Senior Notes may…
Material weakness in IT controls over financial reporting was remediated and disclosure removed. Easing of a previously disclosed control deficiency is material.
A material weakness in our internal control over financial reporting could result in material misstatements in our financial statements and cause us to fail to meet our reporting and financial…
New disclosure of legislative risks to Medicare/Medicaid/ACA affecting demand and pricing; expanded international reimbursement risks with government pricing pressure.
Failure to secure or retain adequate coverage or reimbursement for our products by third-party payors could adversely affect our business, revenue, financial condition, and results of operations. We…
New disclosure of AI/generative AI risks including inappropriate disclosure of personal data and inaccurate AI outputs. Reflects emerging regulatory exposure under EU AI Act.
Risks Related to Information Technology (“IT”) , Privacy and Security We are subject to complex and evolving laws and regulations regarding privacy, data protection, and artificial intelligence…
Added explicit disclosure of increased IT complexity from cloud and AI adoption, with enumerated consequences: regulatory inquiries, litigation, costs, reputational damage, lost revenue, fines.
We rely on the proper function, availability, and security of our products and IT systems; a successful cyber-attack or other breach or disruption of our products or these systems could have a…
New disclosure of AI/emerging tech regulatory burden and IP protection risk. Adds substantive compliance and R&D cost concerns not previously disclosed.
Our new product development initiatives may prove to be ineffective or not commercially successful. A significant element of our strategy is to increase revenue growth by continuing to focus on…
The disclosure centers on the departure of two Board members: Timothy J. Scannell (who served 12 years including 7 years as Chairman) stepping down effective September 3, 2026 for health reasons, and Michael R. Minogue (9 years of service) stepping down effective September 15, 2026 to pursue political candidacy. Both departures are material given Scannell's long tenure and former chairmanship, and the filing explicitly confirms no disagreement with the Company. This is a classic exec_departure event under Item 5.02.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure announces financial results including revenue of $801.7 million (up 23.5%), operating income of $129.7 million, and net income of $95.0 million ($1.37 per diluted share), with the full press release furnished as Exhibit 99.1. The disclosure includes detailed financial statements, guidance updates, and strategic highlights typical of an earnings announcement.
View raw filing on EDGAR →Jonathan J. Mazelsky was appointed as a Class II director of Insulet Corporation, effective July 1, 2026. Mazelsky brings significant executive experience, including 14 years at IDEXX Laboratories where he served as President and CEO, and prior leadership roles at Philips and Agilent.
View raw filing on EDGAR →Insulet disclosed a voluntary medical device correction affecting approximately 7 million Omnipod® Pods due to manufacturing issues (cannula tears), with expected costs up to $50 million in 2026. While the company states it does not anticipate disruption to shipments or guidance changes, the scale of the correction (7 million units), the financial impact ($50 million), and the reputational/regulatory implications of a second related correction within months constitute a material event. This does not fit neatly into existing categories (not a restatement, impairment, or litigation settlement), making "other_material" the most appropriate classification.
View raw filing on EDGAR →Insulet Corp held its 2026 Annual Meeting of Stockholders on May 20, 2026, with voting results disclosed for three proposals: election of three Class I directors (Luciana Borio, Michael R. Minogue, Timothy C. Stonesifer), advisory approval of executive compensation (Say-on-Pay), and ratification of PricewaterhouseCoopers LLP as independent auditor.
View raw filing on EDGAR →Insulet Corp amended and restated its Bylaws to establish exclusive forum selection provisions for derivative actions, fiduciary duty claims, and Securities Act claims, affecting shareholders' litigation rights and corporate governance.
View raw filing on EDGAR →